Show simple item record

dc.date.accessioned2017-06-30T14:44:44Z
dc.date.available2017-06-30T14:44:44Z
dc.date.issued2017-01-25
dc.identifier.urihttp://hdl.handle.net/10713/6806
dc.descriptionCambridge, Md., Jan. 25, 2017 (GLOBE NEWSWIRE)en_US
dc.language.isoen_USen_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectBET proteinsen_US
dc.subjectBET inhibitorsen_US
dc.subjectConverGeneen_US
dc.subject.lcshUniversity of Maryland, Baltimore. School of Medicineen_US
dc.subject.lcshCancer--Researchen_US
dc.subject.lcshCivin, Curt I.en_US
dc.subject.meshLeukemia--drug therapyen_US
dc.subject.meshLeukemia, Myeloid, Acuteen_US
dc.titleConverGene Announces Sponsored Research Agreement with University of Maryland, Baltimore to Evaluate First-in-class Anti-cancer Agentsen_US
dc.typeArticleen_US
dc.identifier.ispublishedNoen_US
dc.description.urinameFull Texten_US
refterms.dateFOA2019-02-19T18:22:19Z


Files in this item

Thumbnail
Name:
ConverGeneSOMResearchAgreement ...
Size:
17.74Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/